How Human NAD+ Research Should Be Evaluated

How Human NAD+ Research Should Be Evaluated

Human NAD+ research should be evaluated according to the exact intervention, route, formulation, participant population, biological compartment measured, study duration, endpoint, and comparison group. Evidence involving nicotinamide riboside, nicotinamide mononucleotide, nicotinamide, nicotinic acid, direct NAD+ administration, or another NAD-related strategy should not automatically be treated as evidence for the same intervention or the same clinical outcome.

This distinction is central to NAD+ research. Human studies can clarify questions that biochemical pathways and animal models cannot answer directly, but the conclusions should remain limited to the specific intervention and endpoints that were actually studied.

This article is provided for general educational purposes and explains terminology, evidence, and regulatory concepts associated with NAD+ research. It does not establish the regulatory status of any specific InStrips product or determine whether a particular product is appropriate for any person.

A measurable increase in NAD+, an NAD-related metabolite, or another biomarker does not by itself establish clinical effectiveness, improved energy, faster recovery, slower biological ageing, longer life, an appropriate amount, or suitability for a particular use.

What Counts as Human NAD+ Research?

Human NAD+ research can include several different study types.

Examples include:

  • pharmacokinetic studies
  • metabolomic studies
  • biomarker studies
  • randomized controlled trials
  • crossover studies
  • dose-escalation studies
  • observational research
  • pilot studies

These study designs do not answer the same scientific questions.

Begin With the Exact Intervention

The phrase NAD+ research can refer to interventions involving different compounds.

These may include:

  • NAD+ itself
  • nicotinamide riboside
  • nicotinamide mononucleotide
  • nicotinamide
  • nicotinic acid
  • other experimental NAD-related compounds

Evidence involving one intervention should not automatically be attributed to another.

NAD+ and NAD+ Precursors Are Not the Same Intervention

NAD+ precursors are molecules that can participate in biological pathways involved in NAD+ synthesis or recycling.

Direct administration of NAD+ is a different intervention from administering a precursor.

These approaches may differ in:

  • absorption
  • metabolism
  • cellular uptake
  • tissue distribution
  • conversion pathways
  • measured metabolites

A study of nicotinamide riboside therefore does not automatically establish what occurs after direct NAD+ administration.

Nicotinamide Riboside and NMN Should Be Evaluated Separately

Nicotinamide riboside and nicotinamide mononucleotide are both associated with NAD+ metabolism, but they are distinct molecules.

They can differ in:

  • chemical structure
  • metabolic conversion
  • transport pathways
  • pharmacokinetics
  • formulation
  • human evidence base

Results from one precursor should not be transferred automatically to the other.

Route of Administration Matters

Human NAD-related interventions may be administered orally, intravenously, or through another investigated route.

Route can affect:

  • systemic appearance
  • metabolite formation
  • peak concentration
  • total exposure
  • first-pass metabolism
  • administration-related safety

An oral study should not automatically support conclusions about intravenous administration.

Intravenous NAD+ Research Should Be Identified Specifically

Intravenous administration introduces an NAD-related formulation directly into systemic circulation rather than relying on gastrointestinal absorption.

Research involving intravenous NAD+ should identify:

  • the exact formulation
  • infusion amount
  • infusion rate
  • duration
  • participant population
  • measured analytes
  • safety observations

A commercial infusion program should not be assumed to match a research protocol solely because both use the term NAD+.

Oral NAD+ Research Is a Separate Evidence Question

Oral NAD+ formulations face gastrointestinal and metabolic processes that differ from intravenous administration.

Human studies may investigate whether oral administration changes:

  • whole-blood NAD+
  • plasma NAD-related metabolites
  • intracellular NAD-related measurements
  • metabolic flux
  • other biomarkers

A measurable biomarker change does not establish that intact orally administered NAD+ reached every tissue in the same form.

Know What Was Actually Measured

NAD-related human studies may measure different biological materials.

These can include:

  • whole blood
  • plasma
  • serum
  • peripheral blood mononuclear cells
  • skeletal muscle
  • urine
  • other sampled tissues

A result in one compartment should not automatically be described as a whole-body or tissue-wide change.

Whole-Blood NAD+ Is Not the Same as Tissue NAD+

Whole blood contains multiple cell types and circulating components.

A whole-blood NAD+ measurement does not establish NAD+ concentrations in:

  • skeletal muscle
  • brain
  • liver
  • heart
  • adipose tissue
  • other organs

Tissue-specific conclusions require tissue-specific evidence whenever feasible.

Human NAD+ Levels May Not Decline Uniformly With Age

The idea that NAD+ universally declines throughout the human body with age is often presented more confidently than the human evidence supports.

Recent human research has found that age-related patterns can differ according to:

  • tissue
  • measurement method
  • participant population
  • sample handling
  • metabolic context

Age-related findings from rodents should not automatically be described as established across human tissues.

Blood NAD+ May Not Be a Universal Ageing Biomarker

Recent human data have challenged the assumption that whole-blood NAD+ necessarily declines in a simple linear way with age.

This illustrates why a biomarker should be validated for the intended purpose before being used as an indicator of biological ageing.

A useful ageing biomarker would require evidence concerning:

  • reproducibility
  • age association
  • biological relevance
  • within-person stability
  • relationship to meaningful outcomes

Assay Methodology Matters

NAD+ and related metabolites can be difficult to measure accurately because sample handling and analytical conditions may affect the result.

Important methodological details can include:

  • sample collection
  • time to processing
  • temperature
  • storage conditions
  • extraction method
  • analytical platform
  • reference standards

Results from different assays should not be assumed to be directly interchangeable.

Mass Spectrometry and Enzymatic Assays Can Answer Different Questions

Human NAD+ studies may use mass spectrometry, enzymatic cycling methods, or other analytical approaches.

Methods may differ in:

  • specificity
  • sensitivity
  • ability to distinguish related metabolites
  • sample requirements
  • quantification range

Analytical method should therefore be considered when comparing studies.

Baseline Levels Matter

Participants can begin a study with different NAD-related measurements.

Baseline differences may reflect:

  • age
  • diet
  • health status
  • medication use
  • metabolic characteristics
  • sample timing
  • laboratory variation

Changes from baseline should be interpreted alongside the absolute values and study design.

Biochemical Target Engagement Is Not the Same as a Clinical Outcome

A study may show that an intervention increased NAD+ or another NAD-related metabolite.

This can support evidence of biochemical target engagement.

It does not independently establish:

  • greater physical energy
  • improved exercise capacity
  • faster recovery
  • better cognition
  • slower ageing
  • reduced disease risk

Those outcomes require separate measurement.

Magnitude of Biomarker Change Matters

A statistically detectable increase in NAD+ may be small or large.

Interpretation should consider:

  • absolute change
  • percentage change
  • confidence interval
  • between-person variability
  • duration of the change
  • relationship to functional endpoints

A larger biochemical change is not automatically a larger clinical effect.

The Timing of Measurement Matters

NAD-related metabolites may change over hours, days, or weeks.

A study measuring one time point may miss:

  • an earlier peak
  • a temporary response
  • return to baseline
  • delayed metabolic changes

Sampling schedules should match the expected biology of the intervention.

Short-Term Biomarker Studies Have Limited Scope

A study lasting several days may help determine whether an intervention changes a biochemical measurement.

It usually cannot establish:

  • long-term clinical outcomes
  • healthy-ageing effects
  • rare adverse events
  • long-term metabolic adaptation
  • durable functional changes

Human Trials of NAD+ Precursors Often Show Stronger Biomarker Effects Than Clinical Effects

Human trials of NAD+ precursors have frequently reported increases in NAD-related metabolites or other biochemical indicators.

Functional and clinical outcomes have been more variable.

Studies may report:

  • no significant change in one endpoint
  • an effect in another endpoint
  • subgroup-specific findings
  • changes that are statistically detectable but clinically uncertain

This difference between target engagement and outcome evidence should remain explicit.

Human Trials Should Be Evaluated Outcome by Outcome

A study can produce a positive biomarker result while showing no significant change in:

  • exercise performance
  • muscle function
  • insulin sensitivity
  • vascular measurements
  • cognitive tests
  • quality-of-life measures

The biomarker result should not be used to overwrite the measured clinical outcome.

Healthy Volunteers and Clinical Populations Are Different

Some NAD-related studies enroll healthy adults, while others enroll participants with defined conditions.

Healthy-volunteer findings may help characterize:

  • tolerability
  • bioavailability
  • metabolite changes
  • short-term pharmacology

They do not automatically predict clinical outcomes in people with disease.

Older Adults Are Not One Uniform Population

Ageing studies may include participants with wide differences in:

  • fitness
  • metabolic health
  • medications
  • diet
  • body composition
  • chronic conditions

A result from one selected older-adult population should not automatically be generalized to all older people.

Small Sample Sizes Limit Certainty

Many early NAD-related studies include relatively small participant groups.

Small samples can make it difficult to characterize:

  • rare adverse events
  • subgroup effects
  • modest functional changes
  • between-person variability
  • long-term outcomes

Randomization Strengthens Some Comparisons

Randomized controlled trials can reduce systematic differences between intervention and control groups.

Randomization does not remove every limitation involving:

  • small sample size
  • short follow-up
  • poor endpoint selection
  • missing data
  • limited generalizability

Placebo Control Can Be Important for Subjective Outcomes

Outcomes involving fatigue, energy, wellbeing, or perceived recovery can be influenced by expectation.

A placebo-controlled design can help separate:

  • expectation
  • study participation effects
  • natural variation
  • intervention-related changes

Blinding Reduces Some Forms of Bias

Participant and investigator knowledge of treatment assignment can affect:

  • symptom reporting
  • behavior
  • outcome assessment
  • study retention

Blinding can therefore be particularly useful when outcomes have subjective components.

Crossover Studies Have Strengths and Limitations

In a crossover study, participants may receive both intervention and control during different periods.

This can reduce between-person variability.

Researchers still need to consider:

  • washout duration
  • carryover effects
  • period effects
  • changing baseline conditions

Functional Endpoints Should Be Defined Before the Trial

If a study aims to evaluate exercise capacity, recovery, cognition, or another outcome, that endpoint should be defined clearly.

Relevant features include:

  • measurement method
  • primary versus secondary status
  • timing
  • statistical analysis plan
  • minimum clinically important difference

Multiple Endpoints Increase the Risk of Chance Findings

NAD-related trials may measure many biomarkers and functional outcomes.

When numerous comparisons are performed, some differences can appear statistically significant by chance.

Readers should determine:

  • which outcomes were primary
  • which were exploratory
  • whether statistical adjustments were used
  • whether findings were replicated

Subgroup Findings Need Confirmation

A trial may identify an apparent effect only in a subgroup.

Subgroups may be defined by:

  • age
  • sex
  • baseline NAD+
  • metabolic status
  • fitness

Post hoc subgroup results can generate hypotheses but often require confirmation in a study designed for that question.

Statistical Significance Is Not Clinical Significance

A statistically significant difference may be small.

Clinical interpretation should consider:

  • effect size
  • confidence interval
  • baseline value
  • measurement variability
  • clinical importance

Null Results Are Part of the Evidence Base

Human NAD-related trials have not produced uniformly positive functional outcomes.

Null findings are scientifically important because they help identify:

  • which endpoints may not change
  • which populations may not respond
  • which interventions need further study
  • where preclinical expectations may not translate

They should not be omitted from a balanced review.

Negative Findings Should Not Be Reframed as Hidden Successes

A trial that fails to show a predefined outcome should not be described as successful merely because one secondary biomarker changed.

The primary outcome and study hierarchy should remain clear.

Animal NAD+ Research Does Not Establish Human Outcomes

Animal models have contributed substantially to understanding NAD+ metabolism.

Rodent studies may investigate:

  • metabolism
  • mitochondrial function
  • age-related changes
  • muscle function
  • neurological outcomes
  • lifespan

These results do not automatically predict equivalent effects in humans.

Rodent Lifespan Findings Are Especially Difficult to Translate

Animal longevity studies can examine lifespan directly under controlled conditions.

Human healthy-ageing research generally cannot reproduce the same experiment because of:

  • much longer timescales
  • greater environmental variation
  • ethical constraints
  • multiple competing health factors

Animal lifespan findings should therefore not be converted directly into human longevity claims.

Metabolic Pathways Are Conserved but Not Identical

NAD+ biology is fundamental across many species, but quantitative responses can differ.

Translation can be affected by:

  • metabolic rate
  • tissue NAD+ turnover
  • enzyme expression
  • dose relative to body size
  • diet
  • lifespan

Human Tissue Data Remain Relatively Sparse

Recent reviews emphasize that human tissue-specific NAD+ data remain limited compared with the preclinical literature.

This matters because blood measurements cannot establish how an intervention changes NAD+ metabolism in every organ.

Muscle Biopsy Studies Can Provide More Direct Tissue Evidence

Skeletal-muscle biopsies can allow researchers to measure NAD-related metabolites in the target tissue.

Such studies are more invasive and often include fewer participants.

They can provide useful tissue-specific information while still remaining limited in sample size and generalizability.

Brain NAD+ Is Particularly Difficult to Study Directly

Direct measurement of NAD+ in living human brain tissue is difficult.

Researchers may rely on:

  • imaging approaches
  • indirect biomarkers
  • postmortem tissue
  • peripheral measurements

Each method has limitations.

Blood NAD+ should not automatically be treated as a direct measurement of brain NAD+.

Human Safety Evidence Must Match Duration

Short-term studies can provide short-term tolerability data.

They may not establish:

  • multi-year safety
  • rare adverse events
  • long-term metabolic effects
  • effects in vulnerable populations
  • interaction with chronic medications

Long-Term Safety Requires Larger and Longer Studies

An intervention that appears well tolerated for several weeks may require additional evaluation over months or years.

Longer studies can help characterize:

  • persistent laboratory changes
  • adverse events
  • metabolic adaptation
  • participant adherence
  • durability of biomarker effects

Interindividual Variability Matters

People may respond differently to NAD-related interventions.

Variability may involve:

  • baseline NAD metabolism
  • diet
  • genetics
  • microbiome
  • age
  • medications
  • metabolic health

An average group effect may not describe every participant.

Evidence Should Match the Claim

A biomarker claim can be supported by a biomarker study if the measurement is valid.

A claim about exercise recovery requires an exercise-recovery study.

A claim about cognition requires validated cognitive outcomes.

A claim about healthy ageing requires appropriately designed human ageing-related endpoints.

Biomarker Findings Should Not Be Converted Into Clinical Claims

This distinction is examined further in why NAD+ biomarker changes do not automatically establish clinical outcomes.

The fact that an intervention changes a biochemical variable shows that something measurable occurred. It does not establish the practical meaning of that change without outcome evidence.

Current Reviews Emphasize the Human Evidence Gap

Recent reviews of NAD+ precursor research have emphasized that biochemical target engagement in humans is more consistently demonstrated than broad clinical effectiveness.

The 2025 Nature Metabolism review of NAD+ precursor supplementation in human ageing notes that human tissue data remain sparse and that translation from rodent studies is not straightforward.

Review findings should still be connected to the exact compound, population, and outcome being discussed.

Final Perspective

Human NAD+ research should be evaluated intervention by intervention, tissue by tissue, and outcome by outcome.

Studies showing changes in NAD+ or related metabolites can demonstrate biochemical target engagement, but they do not automatically establish improvements in energy, recovery, cognition, metabolic health, healthy ageing, or longevity.

Accurate evaluation should identify the exact compound, route, formulation, biological compartment, analytical method, participant population, study design, duration, primary endpoint, safety findings, and limitations before translating a human NAD-related study into a broader conclusion.

Back to blog